Evidence map›Paper›PMID 23313112›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2013

Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.

Rosalind H E Chong, Emilio Gonzalez-Gonzalez, Maria F Lara, Tycho J Speaker, Christopher H Contag, Roger L Kaspar, Sion A Coulman, Rachel Hargest, James C Birchall

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 116 citations in OpenAlex.

  1. Smart micro/nanoneedles for gene delivery.Iranian journal of basic medical sciences · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Microneedle systems for delivering nucleic acid drugs.Journal of pharmaceutical investigation · 2022
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. siRNA Drugs: Here to Stay.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rosalind H E ChongSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Emilio Gonzalez-Gonzalez
Maria F Lara
Tycho J Speaker
Christopher H Contag
Roger L Kaspar
Sion A Coulman
Rachel Hargest
James C Birchall
Stanford Medicine · USCardiff University · GBUniversity Hospital of Wales · GB

Funding

Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAsR44AR056559 · NIAMS · TRANSDERM, INC. · PI KASPAR, ROGER L · 2011 to 2013
$4.1M
Delivery of biologically active nucleic acids to epidermal cellsRC2AR058955 · NIAMS · TRANSDERM, INC. · PI CONTAG, CHRISTOPHER H, KASPAR, ROGER L · 2009 to 2010
$2.8M
NIAMS NIH HHS R44 AR056559NIAMS NIH HHS RC2 AR058955
6 · The paper itself

Abstract

The development of siRNA-based gene silencing therapies has significant potential for effectively treating debilitating genetic, hyper-proliferative or malignant skin conditions caused by aberrant gene expression. To be efficacious and widely accepted by physicians and patients, therapeutic siRNAs must access the viable skin layers in a stable and functional form, preferably without painful administration. In this study we explore the use of minimally-invasive steel microneedle devices to effectively deliver siRNA into skin. A simple, yet precise microneedle coating method permitted reproducible loading of siRNA onto individual microneedles. Following recovery from the microneedle surface, lamin A/C siRNA retained full activity, as demonstrated by significant reduction in lamin A/C mRNA levels and reduced lamin A/C protein in HaCaT keratinocyte cells. However, lamin A/C siRNA pre-complexed with a commercial lipid-based transfection reagent (siRNA lipoplex) was less functional following microneedle coating. As Accell-modified "self-delivery" siRNA targeted against CD44 also retained functionality after microneedle coating, this form of siRNA was used in subsequent in vivo studies, where gene silencing was determined in a transgenic reporter mouse skin model. Self-delivery siRNA targeting the reporter (luciferase/GFP) gene was coated onto microneedles and delivered to mouse footpad. Quantification of reporter mRNA and intravital imaging of reporter expression in the outer skin layers confirmed functional in vivo gene silencing following microneedle delivery of siRNA. The use of coated metal microneedles represents a new, simple, minimally-invasive, patient-friendly and potentially self-administrable method for the delivery of therapeutic nucleic acids to the skin.

Indexed as

Drug Delivery SystemsGene SilencingStainless SteelAnimalsCell Culture TechniquesCell LineDrug CompoundingEquipment DesignGreen Fluorescent ProteinsHumansKeratinocytesLamin Type AMiceMice, TransgenicMicroinjectionsNeedlesGreen Fluorescent ProteinsLamin Type ALMNA protein, humanRNA, MessengerRNA, Small InterferingStainless Steel

Identifiers

PMID23313112
PMCPMC3594125
OpenAlexW2057016701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.